P G Rose

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. ncbi request reprint Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
    P G Rose
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Int J Gynecol Cancer 15:18-22. 2005
  2. ncbi request reprint Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity
    Peter G Rose
    Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA
    Gynecol Oncol 89:429-33. 2003
  3. ncbi request reprint A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
  4. ncbi request reprint Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
  5. ncbi request reprint Stage IIB-IVA cancer of the cervix
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Cancer J 9:404-14. 2003
  6. ncbi request reprint Combined-modality therapy of locally advanced cervical cancer
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Clin Oncol 21:211s-217s. 2003
  7. ncbi request reprint Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy
    P G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio, 44106, USA
    Gynecol Oncol 82:17-21. 2001
  8. ncbi request reprint Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages
    P G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 82:323-8. 2001
  9. ncbi request reprint Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study
    J P Curtin
    Department of Obstetrics and Gynecology, Cornell University Medical College, NY, USA
    J Clin Oncol 19:1275-8. 2001
  10. ncbi request reprint Combined radiation therapy and chemotherapy for carcinoma of the cervix
    P G Rose
    Division of Gynecologic Oncology, and the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Cancer J 7:86-94. 2001

Collaborators

Detail Information

Publications59

  1. ncbi request reprint Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
    P G Rose
    Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Int J Gynecol Cancer 15:18-22. 2005
    ....
  2. ncbi request reprint Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity
    Peter G Rose
    Case Western Reserve University, Ireland Cancer Center, Cleveland, OH 44106, USA
    Gynecol Oncol 89:429-33. 2003
    ....
  3. ncbi request reprint A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University, Division of Gynecologic Oncology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Gynecol Oncol 88:130-5. 2003
    ..The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients...
  4. ncbi request reprint Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 89:267-70. 2003
    ..To evaluate prolonged oral etoposide in nonsquamous cell carcinoma of the cervix, the current phase II trial was conducted...
  5. ncbi request reprint Stage IIB-IVA cancer of the cervix
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Cancer J 9:404-14. 2003
    ..However, these improvements, currently practiced in developed countries, must be implemented in underdeveloped countries which have the greatest burden of this disease...
  6. ncbi request reprint Combined-modality therapy of locally advanced cervical cancer
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109, USA
    J Clin Oncol 21:211s-217s. 2003
    ..The potential role of biologic agents in combination with chemoradiotherapy also needs to be examined in locally advanced cervical cancer...
  7. ncbi request reprint Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy
    P G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, Ohio, 44106, USA
    Gynecol Oncol 82:17-21. 2001
    ..CONCLUSIONS: These results suggest that despite technical modifications the sensitivity of PET before second-look laparotomy for small-volume persistent disease is low...
  8. ncbi request reprint Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages
    P G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 82:323-8. 2001
    ....
  9. ncbi request reprint Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study
    J P Curtin
    Department of Obstetrics and Gynecology, Cornell University Medical College, NY, USA
    J Clin Oncol 19:1275-8. 2001
    ..The overall response rate was 31%. The primary and dose-limiting toxicity was neutropenia. CONCLUSION: The response rate to paclitaxel exceeds the rates reported using other single agents in nonsquamous carcinoma of the cervix...
  10. ncbi request reprint Combined radiation therapy and chemotherapy for carcinoma of the cervix
    P G Rose
    Division of Gynecologic Oncology, and the Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Cancer J 7:86-94. 2001
    ..This review summarizes studies of sequential and concurrent combinations of chemotherapy and radiation therapy for the treatment of cervical cancer, as well as the recent controversies related to this treatment...
  11. ncbi request reprint Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study
    P G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospital of Cleveland, OH 44106, USA
    Gynecol Oncol 62:100-2. 1996
    ..8%. Grade 3 peripheral neurotoxicity occurred in 3.4%. There were no objective responses, demonstrating that this agent is useful in previously treated squamous cell carcinoma of the cervix...
  12. doi request reprint Malignant melanoma of the vulva: an extension of cutaneous melanoma?
    K M Moxley
    Division of Gynecologic Oncology, University of Oklahoma HSC, Oklahoma City, OK, USA
    Gynecol Oncol 122:612-7. 2011
    ....
  13. ncbi request reprint Significance of cytologically normal endometrial cells in cervical smears from postmenopausal women
    V R Sarode
    Department of Pathology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA
    Acta Cytol 45:153-6. 2001
    ..Women who were not on HRT had a higher incidence of endometrial pathology...
  14. ncbi request reprint Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer
    M Rodriguez
    University Hospital of Cleveland, Case Western Reserve University, Ireland Comprehensive Cancer Center, USA
    Am J Obstet Gynecol 185:370-4. 2001
    ..Long-term survival of patients treated with radical trachelectomy for early invasive cervical cancer are yet to be determined...
  15. ncbi request reprint Locally advanced cervical cancer
    P G Rose
    Division of Gynecologic Oncology, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106, USA
    Curr Opin Obstet Gynecol 13:65-70. 2001
    ..The use of concurrent chemotherapy and radiation therapy has resulted in a significant increase in patient survival. Our understanding of cervical tumor biology has the potential for further improvements...
  16. ncbi request reprint Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006?
    P G Rose
    Division of Gynecologic Oncology, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA
    Ann Oncol 17:x224-9. 2006
  17. ncbi request reprint Chemoradiotherapy for cervical cancer
    P G Rose
    Division of Gynecologic Oncology, University Hospitals of Cleveland and The Ireland Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
    Eur J Cancer 38:270-8. 2002
    ..e. concurrently with radiation therapy), as the new standard of therapy for cervical cancer...
  18. ncbi request reprint Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report
    William C McBee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 105:244-7. 2007
    ..Mixed yolk sac tumors of the ovary are biologically aggressive even in early stage disease...
  19. pmc Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials
    Bradley J Monk
    Department of Ob Gyn, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, and Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026, USA
    Gynecol Oncol 105:427-33. 2007
    ..To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation...
  20. ncbi request reprint Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
    ....
  21. ncbi request reprint Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group
    Paul A DiSilvestro
    Program in Womens Oncology, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, and Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City 73190, USA
    Gynecol Oncol 103:1038-42. 2006
    ..To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer...
  22. ncbi request reprint Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
    ..A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum number of days) of sequential oral topotecan and oral etoposide...
  23. ncbi request reprint Docetaxel in ovarian cancer
    Pedro F Escobar
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, A 81, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Expert Opin Pharmacother 6:2719-26. 2005
    ..This article reviews the rationale and indications for the use of docetaxel in ovarian cancer...
  24. ncbi request reprint Role of surgery in ovarian carcinoma
    Amanda Nickles Fader
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2873-83. 2007
    ..The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed...
  25. ncbi request reprint Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    Fiona Simpkins
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A81, Cleveland, OH, 44195, USA
    Gynecol Oncol 107:118-23. 2007
    ..Since the initial report of this complication, we have limited bevacizumab treatment to patients without: 1) clinical symptoms of bowel obstruction 2) evidence of rectosigmoid involvement on pelvic exam 3) bowel involvement on CT scan...
  26. ncbi request reprint Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:2804-10. 2007
    ....
  27. doi request reprint A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation Case Western Reserve University, Cleveland, OH 44195, USA
    Am J Clin Oncol 31:476-80. 2008
    ....
  28. pmc Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
    Mark A Morgan
    Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Gynecol Oncol 110:329-35. 2008
    ....
  29. pmc Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 109:329-34. 2008
    ..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
  30. pmc Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 109:323-8. 2008
    ..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
  31. ncbi request reprint Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    J Clin Oncol 26:83-9. 2008
    ..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
  32. ncbi request reprint Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73104, USA
    Gynecol Oncol 107:398-403. 2007
    ..Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers. We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison...
  33. ncbi request reprint Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam
    J Clin Oncol 25:3621-7. 2007
    ..The purpose of this study was to identify factors predictive of poor prognosis in a similarly treated population of women with advanced EOC...
  34. ncbi request reprint A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study
    Peter G Rose
    Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 107:274-9. 2007
    ..To determine the maximum tolerated dose (MTD) of gemcitabine followed by cisplatin that can be administered weekly during pelvic radiation therapy in patients with locally advanced cervical cancer...
  35. ncbi request reprint A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma
    Peter G Rose
    MetroHealth Medical Center, Cleveland, Ohio 44195, USA
    Gynecol Oncol 99:714-9. 2005
    ..This phase I/II trial combined weekly topotecan, which is less myelosuppressive than the standard 5-day regimen, with carboplatin in patients with potentially platinum-sensitive relapsed ovarian or peritoneal carcinoma (PS-OVCa/PCa)...
  36. ncbi request reprint Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study
    Lari Wenzel
    Center for Health Policy Research, Division of General Internal Medicine, College of Medicine, University of California, Irvine, USA
    J Clin Oncol 23:5605-12. 2005
    ....
  37. ncbi request reprint A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Cleveland, Ohio 44109, USA
    Gynecol Oncol 85:136-9. 2002
    ..In an effort to explore second-line therapy in ovarian, peritoneal, and tubal carcinoma, a phase I trial combining prolonged oral etoposide and liposomal doxorubicin was conducted by the Gynecologic Oncology Group...
  38. ncbi request reprint Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma
    Peter G Rose
    Case Western Reserve University and Ireland Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Ohio 44106, USA
    Gynecol Oncol 88:17-21. 2003
    ..We evaluated the cisplatin and gemcitabine regimen in patients with platinum refractory and multidrug refractory ovarian and peritoneal carcinoma...
  39. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  40. ncbi request reprint Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel
    Peter G Rose
    Case Western Reserve University and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland, OH 44109, USA
    Gynecol Oncol 91:423-5. 2003
    ..Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy...
  41. ncbi request reprint Chemoradiation for locally advanced cervical cancer: does it help?
    Peter G Rose
    J Clin Oncol 20:891-3. 2002
  42. ncbi request reprint Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer
    Peter G Rose
    MetroHealth Medical Center, Cancer Care Pavilion, Room 2017, 2500 MetroHealth Dr, Cleveland, OH 44109, USA
    Semin Oncol Nurs 19:25-35. 2003
    ..To review chemotherapy options for patients with newly diagnosed or relapsed advanced ovarian cancer...
  43. ncbi request reprint Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
    Katherine Y Look
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:644-7. 2004
    ..To determine the antitumor activity and toxicity profile of gemcitabine as second-line chemotherapy in patients with recurrent or persistent uterine leiomyosarcoma (LMS)...
  44. ncbi request reprint Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer
    Rachel A Dubay
    Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH 44109 1998, USA
    Gynecol Oncol 94:121-4. 2004
    ..To analyze the toxicity profile and long-term outcomes of patients receiving carboplatin with concurrent radiation for locally advanced cervical cancer...
  45. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  46. ncbi request reprint Secondary surgical cytoreduction for advanced ovarian carcinoma
    Peter G Rose
    Case Western Reserve University and the Division of Gynecologic Oncology, MetroHealth Medical Center, Cleveland, USA
    N Engl J Med 351:2489-97. 2004
    ....
  47. ncbi request reprint A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma
    Peter G Rose
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA
    Gynecol Oncol 96:296-300. 2005
    ..We studied weekly paclitaxel and 3-week carboplatin in potentially platinum-sensitive recurrent ovarian and peritoneal carcinoma...
  48. ncbi request reprint Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer
    Peter G Rose
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A 81, Cleveland, Ohio 44195, USA
    Oncologist 10:205-14. 2005
    ....
  49. ncbi request reprint Management of locally advanced cervical cancer
    Luis A Rojas-Espaillat
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Oncol 17:485-92. 2005
    ..This review will critically evaluate the evidence supporting the available treatment modalities for locally advanced cancer of the uterine cervix...
  50. ncbi request reprint Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology
    Robert Kim
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, OH 44195, USA
    Surg Oncol Clin N Am 14:267-88. 2005
  51. ncbi request reprint Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 22:343-9. 2004
    ..This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and toxicity of irofulven in patients with previously treated adenocarcinoma of the endometrium...
  52. ncbi request reprint Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review
    Peter G Rose
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Ohio, USA
    Expert Opin Pharmacother 3:1245-9. 2002
    ..In conclusion, cisplatin-based chemoradiation regimens increased mean survival at an acceptable cost per life-year gained in both the in-patient and out-patient settings...
  53. ncbi request reprint Arterial thrombosis in a gynecologic oncology patient: evaluation and management
    Andrew E Green
    Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Gynecol Oncol 87:228-30. 2002
    ..Presentation, evaluation, and treatment varied considerably in all previous reports of arterial thrombosis associated with any malignancy...
  54. doi request reprint Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study
    Michael A Gold
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Cancer 112:1954-63. 2008
    ....
  55. ncbi request reprint Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value
    Peter G Rose
    Obstet Gynecol 101:1022; author reply 1023. 2003
  56. ncbi request reprint Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study
    Paula M Fracasso
    Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Gynecol Oncol 103:523-6. 2006
    ..A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy...
  57. ncbi request reprint The flower looks as good as its bud
    Peter G Rose
    Am J Obstet Gynecol 197:443-4. 2007
  58. pmc Pegylated liposomal doxorubicin in ovarian cancer
    Andrew E Green
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Nanomedicine 1:229-39. 2006
    ....
  59. ncbi request reprint Innovations in the treatment of invasive cervical cancer
    Frederick B Stehman
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202 5274, USA
    Cancer 98:2052-63. 2003
    ..Research advances in both diagnosis and treatment are expected to improve therapy and outcomes...